Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Kymab Limited currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 3 distinct examiners, indicating that each pending case is being handled by a different individual. Furthermore, the portfolio is active in 3 distinct art units, which suggests a range of technical focuses within the broader biotechnology field. This lack of concentration means that the company must manage a variety of examination styles and art unit-specific requirements simultaneously.
OGUNBIYI, OLUWATOSIN A is the busiest examiner for the company, currently overseeing 1 pending office action. Given that the busiest examiner pending count is 1, the 3 pending office actions are spread evenly among the 3 distinct examiners. This distribution requires practitioners to be versatile, as they cannot rely on a single examiner's patterns to predict outcomes across the portfolio. The alignment of 3 pending office actions with 3 distinct examiners and 3 distinct art units highlights a decentralized prosecution strategy in the Biotechnology & Pharmaceuticals sector, necessitating a case-by-case approach for each application.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (40%) |
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
| ROONEY, NORA MAUREEN | 1 | 60.3% | +23.6% |
| LI, RUIXIANG | 1 | 59.5% | +18.6% |
| SINGH, ANOOP KUMAR | 1 | 43.0% | +67.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634191 | PHARMACEUTICAL FORMULATIONS CONTAINING ANTI-OX40L ANTIBODIES | JOHNSON, TIRONE DEREK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18592425 | ANTI-PD-L1 AND IL-2 CYTOKINES | ROONEY, NORA MAUREEN | 42d overdue |
| 16905537 | Animal Models and Therapeutic Molecules | SINGH, ANOOP KUMAR | 22d |
| 18713540 | Antibodies for Use as Therapeutics Against Bacterial Infections | OGUNBIYI, OLUWATOSIN A | — |
| 18510228 | TREATMENT OF PD-L1 NEGATIVE OR LOW EXPRESSING CANCER WITH ANTI-ICOS ANTIBODIES | LI, RUIXIANG | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1641 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713540 | Antibodies for Use as Therapeutics Against Bacterial Infections | OGUNBIYI, OLUWATOSIN A | 1645 | §112 | Non-Final OA | — | Pending | May 24, 2024 |
| 18634191 | PHARMACEUTICAL FORMULATIONS CONTAINING ANTI-OX40L ANTIBODIES | JOHNSON, TIRONE DEREK | — | §102§103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18592425 | ANTI-PD-L1 AND IL-2 CYTOKINES | ROONEY, NORA MAUREEN | 1641 | DP | Final Rejection | 42d overdue | Pending | Feb 29, 2024 |
| 18510228 | TREATMENT OF PD-L1 NEGATIVE OR LOW EXPRESSING CANCER WITH ANTI-ICOS ANTIBODIES | LI, RUIXIANG | — | §112 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 16905537 | Animal Models and Therapeutic Molecules | SINGH, ANOOP KUMAR | 1632 | §112DP | Final Rejection | 22d | Pending | Jun 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial